A 002 - MeiraGTx

Drug Profile

A 002 - MeiraGTx

Alternative Names: A002 - MeiraGTx; AAV2/8-hCARp.hCNGB3

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MeiraGTx
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colour vision defects

Most Recent Events

  • 17 Oct 2017 Pharmacodynamics data from a preclinical trial in Colour vision defects released by MeiraGTx
  • 24 Jan 2017 Phase-I/II clinical trials in Colour vision defects in United Kingdom (Intraocular) (NCT03001310)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top